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Background: Macrophage migration inhibitory factor (MIF) is an inflammatory cytokine released mainly from macro-
phages and activated lymphocytes. Both atherosclerosis and abdominal aortic aneurysm (AAA) are inflammatory diseases
tightly linked to the function of these cells. The correlation and contribution of MIF to these human diseases remain
unknown, although a recent rabbit study showed expression of this cytokine in atherosclerotic lesions.
Material and Methods: MIF immunohistochemistry was performed on tissue sections from five normal aortas, seven
atherosclerotic carotids, and six AAAs. A group of 112 men with small AAAs (defined as 3 to 5 cm) was recruited at the
time of diagnosis, had serum samples taken, and was followed annually for 1 to 5 years (mean, 2.9 years) and referred for
surgery if the AAA exceeded 5 cm in diameter. Of this study group, 98 had serum MIF measured with an enzyme-linked
immunosorbent assay and 61 had detectable levels.
Results: In human atherosclerotic and aneurysmal lesions, MIF protein colocalized in macrophages, endothelial cells, and
smooth muscle cells, but normal arteries had negligible MIF expression. Furthermore, serum-MIF levels correlated
significantly with annual expansion rate (r  0.28; P  .005), persisting after adjustment for initial AAA size, smoking
habits, diastolic blood pressure, ankle blood pressure index, and age. After exclusion of 38 cases with MIF levels below
the detection limit, initial AAA size was also significantly correlated with the MIF levels (r  0.42; P  .001), persisting
after adjustment for similar confounders, and the correlation coefficient with expansion rate increased to 0.42 (P .001).
Conclusion: Highly expressed MIF in macrophages, endothelial cells, and smooth muscle cells in lesions from atheroscle-
rosis and AAA and significant association between serum MIF level and AAA initial size and AAA expansion rate in a
group of patients with AAA suggest a potential involvement of this proinflammatory cytokine in the pathogenesis of these
cardiovascular diseases. (J Vasc Surg 2003;37:628-35.)
Macrophage migration inhibitory factor (MIF) is a
pleiotropic cytokine released from macrophages, T lym-
phocytes, and the pituitary gland during inflammatory
responses. The primary function of MIF was originally
considered to be inhibition of macrophage migration.1
Recent observations, however, indicate that this cytokine
also regulates cell proliferation,2 angiogenesis,3 T cell
proliferative response and B cell antibody production,4,5
and matrix metalloprotease (MMP) expression.4,6 Mu-
rine macrophages treated with MIF showed increased
oxidized lipoprotein uptake and degradation.7 These
observations suggest a potential role for MIF in the
pathogenesis of atherosclerosis and AAA because both
are inflammatory diseases that involve substantial im-
mune responses, cell proliferation and differentiation,
neovascularization, and protease upregulation and acti-
vation.8 A recent study from Lin et al9 described MIF
expression in vascular endothelial cells (ECs), smooth
muscle cells (SMCs), and macrophages within rabbit
atherosclerotic lesions, supporting a hypothesis that MIF
is also expressed in human atherosclerotic or aneurysmal
lesions and regulates plaque growth or rupture and vessel
wall dilatation. The identification of molecular markers
for the expansion of small abdominal aortic aneurysms
(AAAs) has importance for management of patients with
From the Department of Medicine, University of Californiaa; the Depart-
ment of Vascular Surgery, Rigshospitaletb; The Leducq Center for
Cardiovascular Research, Department of Medicine, Brigham and
Women’s Hospital and Harvard Medical Schoolc; The Picower Insti-
tute for Medical Researchd; and The Department of Vascular Surgery,
Hospital of Viborg.e
*These two authors contributed equally to this work.
Supported by grants from the National Heart, Lung, and Blood Institute to
G-P. Shi (HL 60942) and P. Libby (HL34636) and from the Danish
Health Research Council, the Foundation of Research in Western Den-
mark, the Danish Heart Foundation, and Viborg County. S. C. Donnelly
was supported by the Welcome Trust.
Competition of interest: none.
Additional material for this article may be found online at www.mosby.
com/jvs.
Reprint requests: Dr Guo-Ping Shi, Division of Pulmonary and Critical Care
Medicine, Surge 203, 90 Medical Center Way, San Francisco, CA 94143
(e-mail: gpshi@itsa.ucsf.edu).
Copyright © 2003 by The Society for Vascular Surgery and The American
Association for Vascular Surgery.
0741-5214/2003/$30.00  0
doi:10.1067/mva.2003.74
628
respect to timing of operative or other interventions. To
date, no studies have linked MIF directly to any type of
cardiovascular disease. This study tested this hypothesis
with localization of MIF expression in normal human
aortas and atherosclerotic lesions and assessment of the
correlation between serum MIF and AAA size and AAA
expansion rate.
METHODS AND MATERIALS
Two studies, a case control study with immunohis-
tostaining and a prospective serologic study of the progres-
sion of small AAA, were used.
Immunohistochemistry. Frozen tissue samples of
human carotid lesions from endarterectomies (n  7),
normal aortas from cardiac transplant donors (n  5), and
AAAs (n  6) were obtained according to experimental
protocols preapproved by the Human Investigative Review
Committee at the Brigham and Women’s Hospital. We
chose these lesions on the basis of the criteria of well-
developed lesions and preserved cellular morphology aim-
ing at identification of the MIF-expressing cell types in
these lesions. Among these seven advanced human carotid
lesions, all had the morphologic features of fibrofatty le-
sions: a substantial number of SMCs in fibrous caps, clus-
ters of macrophages in shoulder areas, and preserved mi-
crovessels. For AAA lesions, we selected the sections with
substantial vessel wall remodeling, clusters of macrophages,
and preserved microvessels for EC detection. Serial cryostat
sections (6m) were fixed in acetone (20° C, 5 minutes),
air dried, and stained with the avidin-biotin-peroxidase
method.10 Sections were treated with 0.3% hydrogen per-
oxide to inhibit endogenous peroxidase activity before
blocking of nonspecific binding of primary antibody with
incubation with 5% species-appropriate normal serum
(Vector Laboratory, Burlingame, Calif). Incubation with
primary goat antihuman MIF antibody (R&D Systems,
Minneapolis, Minn) diluted in phosphate buffered saline
solution supplemented with 5% of the species-appropriate
normal serum was performed for 90 minutes in a wet
chamber at room temperature. Secondary rabbit antigoat
antibodies were applied for 45 minutes (Vector Laborato-
ry), followed by avidin-biotin complex conjugated with
peroxidase (30 minutes; Vectastain ABC kit, Vector Labo-
ratory). The reaction was visualized with 3-amino-9-ethyl
carbazole (Dako, Carpinteria, Calif). Sections were coun-
terstained with Gill’s hematoxylin solution (Sigma, St
Louis, Mo). For colocalization of MIF with SMC and EC,
goat antihuman MIF antibody (1:200) was applied for 90
minutes, followed by biotinylated rabbit antigoat second-
ary antibody for 45 minutes and Texas red-conjugated
streptavidin (Amersham, Arlington Heights, Ill). Subse-
quent to application of the avidin/biotin blocking kit (Vec-
tor Laboratory), antimuscle actin mAb for SMC (1:40;
Enzo Diagnostics, New York, NY), or anti-CD31 mono-
clonal antibody for EC (1:35; Dako), was added and sec-
tions were incubated overnight at 4° C. Subsequently, bi-
otinylated horse antimouse secondary antibodies were
applied for 45 minutes, followed by streptavidin–
fluorescein isothiocyanate (Amersham) for 20 minutes. As
negative controls for human MIF immunostaining, goat
nonimmune serum was applied parallel with goat antihu-
man MIF antibodies.
Cases with serum samples. In 1994, 4404 men (age
range, 65 to 73 years) in Viborg County in Denmark were
randomized to be invited for abdominal ultrasonography at
their regional hospital. The Health Department of Viborg
County collected names and addresses and assigned per-
sonal identification numbers. A doctor and a nurse, spe-
cially trained in ultrasonography, alternated between orga-
nizing the scans and performing the scans. With respect to
the anterior-posterior (AP) aortic diameter, the interob-
server correlation coefficient between the two observers in
50 blinded double measurements was 0.98, the mean dif-
ference was 0.1  0.84 mm (mean  standard deviation,
same for all data shown subsequently; P  .88), the vari-
ability was 1.68 mm, the arithmetic mean of difference was
0.42  0.73 mm, and the arithmetic variability was 1.46
mm.11 The B-mode scans were carried out with a small
Philips SDR 1550 (Philips, Copenhagen, Denmark)
equipped with a linear 4-MHz transducer and caliper light
pen. An AAA was defined as an infrarenal aortic diameter of
30 mm or more, and patients with AAA diameters larger
than 50 mm were referred for surgery. Consequently, AP
diameters were used for follow-up measurements. A subject
with an AAA of 30 to 49 mm was offered yearly follow-up
examinations for assessment of further expansion. The ex-
pansion was calculated as the change in the AP diameter
during the entire observation period transformed to annual
units (last – first measured maximum AP/time).12 On
average, expansion was 2.7 2.1 mm/y, ranging from 0 to
8.5 mm per year. The mean overall change in AP diameter
during the observation period was 8.5 mm  5.3 mm.
Thus, 91.2% of AAAs expanded more than the variability of
the measurement. All the patients with an AAA consulted
the trial doctor for information, examination, and a rescan.
Medical history, present medication, and smoking habits
were recorded (eg, patients with current smoking were
coded as “1” and those without current smoking were
coded as “0”). The highest brachial blood pressure and the
lowest systolic ankle blood pressure also were recorded.
Blood samples were obtained by the nurse or doctor in-
volved in the study to handle each sample in a strict and
standardized way. The serum samples were left at 18° C for
45 minutes before centrifugation. Thereafter, the samples
were stored in multiple aliquots at 80° C until analysis.
Of the 4404 men invited for screening, 3344 (76%) at-
tended. Of these, 141 (4.2%) had AAAs. Nineteen patients
(0.5%) had initial aortic diameters larger than 50 mm and
were referred for surgery and excluded from this follow-up
study, and the rest were offered annual control scans to
check for expansion. Of these, 10 were lost to follow-up
during the first year, mostly because of death or severe
illness. One hundred twelve subjects were followed for
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more than 1 year and, on average, for 2.9 years. Of these
112 cases, 98 had serum MIF levels measured at the entry.
All previous computer hospital-recorded diagnoses of
AAA-associated diseases up to the offer of screening were
loaded into a computer for each patient. The hospital
records were originally classified according to the Eighth
World Health Organization classification of diseases.13 The
following three groups among these codes were defined:
hypertension, chronicle obstructive pulmonary disease, and
atherosclerotic manifestations (including acute myocardial
infarction, angina pectoris, arteriosclerosis affecting the
lower limbs, stroke, or transient cerebral ischemia). For
each patient, serum total cholesterol, serum high-density
lipoprotein (HDL), and serum triglycerides were deter-
mined with commercial assays (Sigma), and serum low-
density lipoprotein (LDL) was calculated as: serum choles-
terol  serum HDL  (0.45  serum triglycerides).14
Plasma-total-homocysteines were analyzed with gas chro-
matography–mass spectrometry after reduction with di-
thiothreitol. Deuterated homocysteine was used as the
internal standard.15 The interassay and intraassay coeffi-
cients of variation of the P-tHcy measurements were 5%
and 3% as assessed with internal and external quality assess-
ment.16 Serum creatinine was analyzed with the Vitros
CREA slide on the Vitros 950 Chemistry System (Ortho-
Clinical Diagnostics, Rochester, NY). The creatinine clear-
ance was estimated with the Cockroft-Gault formula:
([140  age]  weight [kg])/(0.825  serum creatinine
[mmol/L]). The forced first second expiratory volume
(FEV1) was measured three times at the initial consultation
with an electronic spirometer (The Vitalograph Escort
Spirometer, Spiropharma, Klampenborg, Denmark) re-
ported to correlate extremely well with a model S wedge
bellows spirometer concerning forced vital capacity and
FEV1.17 The highest volumes were recorded. Calibration
was carried out before each patient. The predicted FEV1
values were calculated with the golden standard formulas
developed by the European Community of Coal and Steel:
(0.043  height)  (0.029  age)  2.49.18
MIF enzyme-linked immunosorbent assay. MIF
levels in serum were measured blindly with a routine MIF-
specific sandwich enzyme-linked immunosorbent assay
with recombinant human MIF as standard.19,20 Briefly,
96-well enzyme-linked immunosorbent assay plates (Im-
munolon II, Dynatech, Chantilly, Va) were coated with 3
g/mL monoclonal anti-MIF (cat #MAB289, R&D Sys-
tems) in phosphate buffered saline solution overnight at
4° C. The plates then were washed and blocked with Su-
perblock (Pierce Chemical Co, Rockford, Ill) containing
2% goat serum. After an additional wash in tris buffered
saline/0.05% Tween 20 (Sigma, St Louis, Mo), the samples
were plated in duplicate and incubated overnight at 4° C.
Captured MIF was visualized with a rabbit anti-MIF poly-
clonal antibody (R102, 1:250 dilution) and detected with
an alkaline phosphatase conjugated goat antirabbit IgG
(1:4000 dilution; Boehringer Mannheim, Indianapolis,
Ind) with p-nitrophenyl phosphate/ethanolamine (Pierce
Chemical Co) as substrate.
Statistics. SPSS 10.0 (SPSS, Inc, Chicago, Ill) was
used to perform the Student t test, the Spearman correla-
tion analysis concerning potential confounders, and, after
exclusion of cases below the detection border, the Pearson
linear correlation analysis and multiple linear regression
analyses for adjustment for potential confounders as age,
smoking habits, diastolic blood pressure, and ankle brachial
blood pressure index (ABI) with initial AAA size and ex-
pansion rate as dependent variables, respectively. MIF lev-
els had a skewed distribution, and the values after natural
logarithm transformation produced an acceptable normal
distribution. These data were used in the subsequent anal-
yses. The studies were approved by the local scientific ethics
committees and reported to the data protection authorities.
RESULTS
Immunohistochemical studies. Normal aortas from
uninvolved individuals contain negligible levels of MIF
antigens (Fig 1 , top panels). Among these seven carotid
Fig 1. MIF expression in normal arteries, atherosclerotic plaques,
and aneurysmal lesions. MIF antigen largely colocalizes with
CD68 macrophages in both atheroma (n 7) and AAA (n 6).
Normal arteries (n  5) contain negligible MIF immunoreactivi-
ties. Goat nonimmune serum (NIS) negative controls for ather-
oma and AAA were shown in bottom two panels. Magnifications are
indicated.
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atherosclerotic lesions, all have clusters of macrophages and
well-developed microvessels. Lipid-laden macrophages
from all of these sections are largely MIF positive (Fig 1). In
addition, ECs from sections with microvessels are also
immunopositive for MIF (Fig 2), suggesting these ECs are
another source for MIF production in atheroma. SMCs, in
contrast, contain much weaker although positive MIF
staining in all examined atheosclerotic lesions (Fig 2 , top
panels). A similar immunostaining pattern was observed in
AAAs. Strong MIF staining colocalized with microvessel
ECs and macrophages in every sample selected from dila-
tated lesions. Figs 1 and 2 showed a representative lesion
with a cluster of macrophages and microvessel ECs (Fig 1
and Fig 2 , bottom two panels). We did not observe sufficient
amounts of MIF immunoreactivity in SMCs in AAAs,
probably because these lesions contain few of these cells.21
Parallel atherosclerotic plaque and AAA lesion sections
were stained with nonimmune goat serum as negative
controls for MIF immunostaining specificity (Fig 1 , bottom
two panels).
Serologic prospective study. The mean of the maxi-
mal AP diameter of the AAA diagnosed with screening was
34.3  4.9 mm, and the mean annual expansion rate was
2.7  2.1 mm/y. The mean blood level of MIF for all 98
cases at entry was 3.14  5.3 ng/mL (Appendix, online
only). This value resembles that reported for healthy sub-
jects (3  1.2 ng/mL).19 Of 98 cases examined, 38 had
MIF levels under the detection limit. Among all 98 AAA
cases, however, the level of circulating MIF was correlated
positively with aneurysmal expansion rate (r  0.28; P 
.005). If cases below the detection limit were excluded, the
correlation coefficient increased to 0.42 (P  .001; Fig 3 ,
A , and Table I). MIF levels were not correlated with initial
AAA sizes (r 0.122; P .231). However, if those values
below the detection limit were omitted from the analysis,
the initial AAA sizes correlated positively and significantly
with the serum MIF levels (r  0.41; P  .001; Fig 3 , B ,
and Table I). The significance of both correlations persisted
after adjustment for age, smoking, diastolic blood pressure,
and ABI, confounders known to affect AAA expansion
(Table II). Circulating MIF levels showed no association
with age, current smoking, diastolic blood pressure, or ABI
in this group of 61 patients. Other confounders, including
homocycteine, serum creatinine, total cholesterol, LDL,
triglycerides, and mean arterial blood pressure, were not
correlated with serum MIF levels (Table III), although they
were associated with atherosclerosis.
Fig 2. MIF expression in ECs and SMCs. In atheroma, MIF (right, red) is also expressed in CD31 ECs (left, green)
and -actin SMCs (left, green). In AAAs, CD31 ECs colocalize with immunoreactive MIF (see insets). In contrast,
SMCs in AAAs express limited levels of MIF. Magnifications are indicated.
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DISCUSSION
This study documented the presence of MIF protein in
macrophages, ECs, and SMCs in human atherosclerotic
and aneurysmal lesions and showed that normal arteries
had negligible levels of MIF immunoreactivity. Further-
more, serum MIF correlated significantly with AAA size
and annual expansion rate.
MIF was first described as a T-cell cytokine1,22 and
then was identified to be a peptide released by pituitary cells
in response to infection or stress.23,24 It is secreted by a
variety of cell types and has been reported to increase in the
circulation during systemic inflammatory diseases, such as
rheumatoid arthritis25 and sepsis.19 Circulating MIF mea-
sured in this study presumably comes from, in addition to
vessel wall ECs, extracellular space from locally inflamed
areas and then leaks to the circulation. It also may be
produced from activated cells in the circulation, such as
lymphocytes or monocytes/macrophages. High serum
MIF levels have been described in rheumatoid arthritis,25
sepsis,19 asthma,26 and uveitis.27 In healthy patients, serum
MIF levels are around 3 ng/mL, close to the mean value of
this study (3.14 ng/mL). MIF is also increased in expres-
sion in inflammatory tissues, such as in rheumatoid arthritis
synovium,25 and in acutely inflamed lung.20 In this study,
patients with such inflammatory diseases were excluded.
We did not include healthy patients as controls because the
selection of appropriate controls and the interpretation of
their results can be controversial. Small differences within
the normal range may be of importance and cannot be
distinguished in a case control study design. This was a
concern that we had in the study of elastin peptides, the
most powerful marker of aneurysmal expansion.28 Com-
puterized data concerning diagnoses at previous hospital
diagnoses were received concerning all the men included in
this study. The MIF levels tended to be higher in men with
hospital admissions for atherosclerosis (defined as admis-
sions for stroke, transient cerebral ischemia, angina pecto-
ris, acute myocardial infarction, or lower limb ischemia; 3.1
versus 2.8; P  .37), for chronic obstructive pulmonary
disease (4.4 versus 2.8; P .16), and for hypertension (3.2
versus 2.8; P  .23). However, these controls are not
optimal because some of the men without such admissions
undoubtly have similar diseases. Furthermore, a proper
control group needs to be gender and age matched. It is
questionable whether it is possible to achieve a control
group consisting of 70-year-old men without atherosclero-
sis including subclinical atherosclerosis. Consequently, we
considered controls of aortas without atherosclerotic le-
sions as optimal for this study. It is always possible that
other nonvascular disease may also contribute to the circu-
lating MIF. For examples, rheumatoid arthritis, uveitis,
sepsis, asthma, autoimmune uveoretinitis, malarial anemia,
glomerulonephritis, chronic colitis, and multiple sclerosis
all have been shown to have altered serum MIF levels.
Therefore, it is difficult to assume gender-matched and
age-matched AAA-free and atherosclerosis-free individuals
are absolutely normal. Although data from this study do
not directly suggest an association of serum MIF levels with
the development of the disease because of the lack of proper
controls as the baseline, the data do suggest a strong
association of MIF with initial AAA size and annual expan-
sion rate among patients with detectable serum MIF anti-
gen. Patients with MIF levels under the detection limit are
excluded from the analysis (Fig 3). This exclusion may
potentially weaken the correlation. However, associations
presented in Fig 3 are internally controlled and therefore
probably more accurately support a potential involvement
of MIF in AAA lesion formation, although no conclusive
statement can be made before more direct evidences are
provided. The MIF correlations were adjusted for poten-
tially confounding variables, such as smoking, diastolic
blood pressure, ABI, and age, which were reported to
influence AAA expansion. Mean arterial blood pressure,
oxidized LDL, total cholesterol, triglycerides, LDL, HDL,
lipoprotein (a), homocysteine, creatinine clearance, and
Fig 3. Scatter plots of correlation between MIF level and AAA
expansion rate and initial AAA size in small AAAs. A, Correlation
of MIF level with AAA expansion rate. Significant positive corre-
lation of serum MIF level (S-Ln [MIF]; ng/mL) with AAA expan-
sion rate (mm/y; r 0.42; P .001). B, Correlation of MIF level
with initial AAA size. AAA initial sizes (mm) associate significantly
with serum MIF level (S-Ln [MIF]; ng/mL; r  0.41; P  .001).
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pulmonary function as confounders were not included in
this model because they have not been found to correlate
with AAA size or expansion rate29 or, as we observed, MIF
levels (Table III). A potential source of bias that could
confound MIF levels would be the presence of inflamma-
tory lesions, such as chronic obstructive pulmonary disease,
which itself is not known to influence aneurysmal progres-
sion. Our immunohistostaining data nevertheless con-
firmed increased expression of MIF in aneurysmal and
atherosclerotic cases compared with controls.
AAA is an inflammatory lesion involving extensive car-
diovascular wall remodeling. Several pathologic events have
been described in the vascular wall, such as leukocyte
adhesion and infiltration, macrophage foam cell formation,
and cytokine secretion, lymphocyte proliferation and acti-
vation, SMC death, and EC migration and neovasculariza-
tion.21,30-32 Most of these pathologic events involve the
action of inflammatory cytokines released from leukocytes
and intrinsic vascular cells. Both atherosclerotic plaques
and AAA lesions have increased expression of proinflamma-
tory cytokines, such as interferon-, interleukin-1	, and
tumor necrosis factor–. Medial destruction in both ath-
erosclerosis and AAA likely results at least in part from an
inflammatory response within the media and adventi-
tia.33,34 Medial and adventitial infiltration by a mixture of
inflammatory cells, including lymphocytes, macrophages,
and even mast cells, characterizes both human atheroscle-
rosis and AAA.1,22 Our data clearly showed an increased
expression of MIF in both atherosclerosis and AAA, al-
though it remains to be further investigated when this
cytokine starts its expression during the pathogenesis. It has
been reported that the expression of MIF is regulated by
other inflammatory cytokines, such as tumor necrosis fac-
tor–,35,36 which has also been linked to the pathogenesis
of both atherosclerosis and AAA.37,38 It is thus possible
that MIF may interact with other proinflammatory or anti-
Table I. Univariate Pearson correlation coefficient (r) matrix for MIF level, initial AAA size, aneurysmal expansion rate,
age, diastolic blood pressure, and ABI in small AAAs*
Ln (MIF) AAA size
Expansion
rate Age Diastolic BP ABI
Ln(MIF) (ng/mL) r 1.000 0.405 0.422 0.024 0.234 0.100
P value .001 .001 .856 .072 .446
AAA size (mm) r 0.405 1.000 0.634 0.099 0.118 0.078
P value .001 .000 .446 .369 .555
Expansion rate (mm/y) r 0.422 0.634 1.000 0.084 0.077 0.057
P value .001 .000 .520 .559 .666
Age (yr) r 0.024 0.099 0.084 1.000 0.133 0.051
P value .856 .446 .520 .310 .701
Diastolic BP (mm Hg) r 0.234 0.118 0.077 0.133 1.000 0.074
P value .072 .369 .559 .310 .572
ABI (%) r 0.100 0.078 0.057 0.051 0.074 1.000
P value .446 .555 .666 .701 .572
*Only patients (n  61) with detectable MIF levels were included.
Ln (MIF), MIF level; BP, blood pressure.
Table II. Multiple linear regression analysis for correlation between aneurysmal expansion rate and MIF level, age,
smoking, diastolic blood pressure, and ABI in small AAAs
Unstandardized
coefficients 	 Standard error
Standardized
coefficients 	 t P value
(Constant) 5.627 5.917 0.951 .346
MIF level (ng/mL) 1.338 0.428 0.409 3.129 .003
Age (y) 8.527E–02 0.081 0.134 1.050 .299
Smoking (yes  1; no  0) 0.114 0.490 0.030 0.233 .816
Diastolic blood pressure (mm Hg) 4.762E–03 0.018 0.035 0.266 .792
Systolic ABI (%) 1.290E–03 0.011 0.015 0.121 .904
Dependent variable: mean annual expansion rate (mm/y).
Table III. Spearman correlation analysis of serum MIF
with other known atherosclerosis promoters
Confounders
Spearman
correlation coefficient
(
) P value
Phomocysteine 0.03 .80
Serum creatinine clearance 0.02 .88
Serum total cholesterol 0.12 .31
Serum low density lipoprotein 0.10 .35
Serum triglycerides 0.02 .91
Mean arterial blood pressure 0.10 .34
Pulmonary function; observed
FEV1/expected FEV1
0.02 .83
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inflammatory cytokines during pathogenesis. The proin-
flammatory features of MIF have been linked to cell prolif-
eration, neovascularization, and even tumor suppressor
gene inactivation. However, heretofore, no data have di-
rectly linked MIF to the pathogenesis of atherosclerosis and
AAA, although several lines of observations suggested the
involvement of MIF in these diseases. MIF augments MMP
expression from synovial fibroblasts,4 prostate epithelial
cells,6 and even osteoblasts.39 These proteolytic enzymes
appear to contribute importantly to the pathogenesis of
both atherosclerosis and AAA33,34 by degrading extracel-
lular matrix proteins, including collagen and elastin. Break-
down of these matrix macromolecules predisposes to ath-
erosclerotic plaque ruptures and expansion of aneurysm.
MIF also induces macrophages to phagocytose oxidized
LDL,7 and oxidized LDL in turn increases macrophage
MIF expression and secretion, producing a self-sustaining
pathway to form foam cells, which produce proteolytic
enzymes40 and serve as a hallmark of fatty streak formation.
Our observations from this study further suggest a possible
involvement of this proinflammatory cytokine in both ath-
erosclerosis and AAA. In addition to its expression in
macrophages, its primary source, it is also found in mi-
crovessel ECs (Fig 2). It is thus plausible that MIF may
enhance the growth of these microvessels, which are impor-
tant for atheromatous and AAA lesion development, a
hypothesis supported by the finding that blockade of MIF
inhibited angiogenesis by 80% in a mouse lymphoma mod-
el.5
However, it remains to be further investigated whether
the expression of MIF in atherosclerosis and AAA plays any
role in the pathophysiology or whether this is just another
hallmark of inflammation. The significant association of
this cytokine with aortic diameter and AAA expansion rate
detected from a group of 98 patients with AAA strongly
suggests its involvement. Further, MMP regulation by MIF
in nonvascular cells4,6,39 suggests a possibility that it also
triggers MMP and possibly cysteine protease expression in
vascular cells, such as SMCs, ECs, and macrophages. None-
theless, this study intimates a novel implication of this
long-standing cytokine in the cardiovascular system.
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